Linda Nelson counts herself lucky to live near a facility devoted to researching and treating Waldenström’s macroglobulinemia, the rare blood cancer for which she has a genetic predisposition. Recently, when a unique opportunity arose to share her geographic good fortune, she responded quickly. Nelson is being monitored at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber/Brigham … Continued
Waldenström’s macroglobulinemia (Waldenström’s) is a slow-growing type of non-Hodgkin lymphoma marked by abnormal levels of an antibody called macroglobulin (IgM). Also known as lymphoplasmacytic lymphoma, Waldenström’s mostly forms in the bone marrow and can hinder the growth of normal blood cells, which can lead to anemia as well as a weakened immune system. Waldenström’s sometimes … Continued
It’s commonly thought that targeted therapy for cancer requires the development of separate drugs for each type and subtype of cancer. The recent approval of the drug ibrutinib (Imbruvica®), however, for Waldenström’s macroglobulinemia (a rare form of lymphoma) shows the opposite to be true: a single agent can be effective against multiple types of cancers, providing … Continued
By Karen Lee Sobol I recently learned that the word “patient” shares a Latin root with the word “compassion.” Any one of us can become a patient, for a number of reasons. For me, hearing a diagnosis of Waldenström’s macroglobulinemia flipped a switch. I became a patient in a big way.